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Abstract
Background: HIV has fuelled the TB epidemic in sub-Saharan Africa. Mortality in patients co-
infected with TB and HIV is high. Managing factors influencing mortality in TB patients might help
reducing it. This study investigates factors associated with mortality including patients' HIV sero-
status, CD4 cell count, laboratory, nutritional and demographic characteristics in AFB smear
positive pulmonary TB patients.
Methods: We studied 887 sputum smear positive PTB patients, between 18 and 65 years of age
receiving standard 8 months anti-TB treatment. Demographic, anthropometric and laboratory data
including HIV, CD4 and other tests were collected at baseline and at regular intervals. Patients
were followed for a median period of 2.5 years.
Results: Of the 887 participants, 155 (17.5%) died, of whom 90.3% (140/155) were HIV-infected,
a fatality of 29.7% (140/471) compared to 3.6% (15/416) among HIV-uninfected. HIV infection, age,
low Karnofsky score, CD4 cell counts and hemoglobin, high viral load, and oral thrush were
significantly associated with high mortality in all patients.
Conclusion: Mortality among HIV-infected TB patients is high despite the use of effective anti-TB
therapy. Most deaths occur after successful completion of therapy, an indication that patients die
from causes other than TB. HIV infection is the strongest independent predictor of mortality in this
cohort.
Background
Worldwide, one out of three people are infected with
Mycobacterium tuberculosis (MTB) [1]. Approximately 7
million new cases of TB and 1.7 million deaths due to TB
were reported in 2006, the last year that global epidemio-
logical data for TB is available [2]. The HIV epidemic has
fuelled the current TB epidemic worldwide and in partic-
ular in sub-Saharan Africa [3].
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HIV is the strongest factor in the development of active
TB; it is estimated that only one out of ten immunocom-
petent persons infected with TB develops active TB in his/
her lifetime; whereas, one out of ten HIV-infected persons
infected with TB will develop active TB every year. Autopsy
studies have shown that 30 to 40% of HIV-infected adults
die from tuberculosis in Africa [4]. On the other hand TB
has been shown to accelerate HIV disease progression to
AIDS and probably early death [5-8].
If untreated, 50-80% of patients with smear-positive TB
die; fortunately TB has an effective treatment. Current
treatment regimens, given under appropriate manage-
ment conditions, are nearly 100% curative for patients
with drug-susceptible organisms. In a poorly imple-
mented TB programme, as many as 30% of patients with
smear-positive TB die; in contrast, death rates in direct
observed treatment of TB (DOTS) programmes through-
out the world are generally less than 5% [9].
Despite reported good and similar responses to anti-TB
treatment in both HIV-infected and uninfected patients
[10,11], mortality of HIV-infected TB patients during and
following treatment is reported to be higher [12,13].
Appropriate management of factors that influences mor-
bidity and mortality may assist in reducing mortality
among TB patients receiving anti TB treatment. We con-
ducted a study among patients with Acid Fast Bacilli (AFB)
sputum smear-positive pulmonary TB in 5 TB treatment
clinics in Dar es Salaam, Tanzania, to determine factors
associated with mortality including patients' HIV sero-sta-
tus, CD4 cell count, AFB concentration in sputum, nutri-
tional, and demographic characteristics.
Methods
Study Population
The study population and recruitment methods have been
described in detail earlier [14]. Briefly, 887 adults with
pulmonary tuberculosis (TB) were enrolled in a rand-
omized trial to examine the effects of micronutrient sup-
plementation on TB treatment failure, relapse, and
mortality. The trial started in April 2000 in Dar es Salaam,
Tanzania and continued until April 2005. The eligibility
criteria for the study included positive sputum smears for
acid-fast bacilli (AFB), age between 18 and 65 years,
Karnofsky performance score of ≥ 40% [15], plan to stay
in Dar es Salaam for 2 years, not being pregnant, and not
having received anti-TB treatment during the previous one
year.
All patients received a daily combination of rifampicin,
isoniazid, pyrazinamide, and ethambutol under direct
observation of a health worker during the first 2 months
(intensive phase) followed by 6 months of self-adminis-
tered daily isoniazid and ethambutol, as per the Tanzania
National TB and Leprosy Programme guidelines. Antiret-
roviral medications were not widely available to most
HIV-infected persons in Tanzania at the time this trial was
conducted.
A written informed consent was obtained from all the
study participants. The institutional review boards of the
Muhimbili University College of Health Sciences, the Tan-
zanian National AIDS Control Program, and the Harvard
School of Public Health approved the study protocol.
Assessment of Predictors and Outcome
At the time of initiation of anti-TB treatment, HIV status
was assessed among consenting patients using 2 sequen-
tial ELISAs (Wellcozyme, Murex Biotech; Enzygnost anti-
HIV1+2, Behring); discrepant results were resolved by
Western Blot test (Genetic Systems). Both pre-test and
post-test counselling was provided. Among HIV-infected
patients, only those with hemoglobin concentration
greater than 7 g/dL were enrolled in the trial.
At the time of randomization, research nurses collected
information on various socio-demographic characteristics
including age, education levels, marital status, and socio-
economic status. Anthropometric measurements were
also obtained using standardized procedures [16] at the
randomization visit as well as during each monthly fol-
low-up visit. Height was measured to the nearest 0.1 cm
using SECA Bodymeter 206 stadiometers, weight to the
nearest 100 g in SECA 700 balance beam scales, and left
mid-upper arm circumference (MUAC) at the midpoint
between the acromion and olecranon to the nearest 0.1
cm using non-stretchable tailor's tapes.
A physician performed a complete physical examination
and assessed HIV disease stage among the HIV-infected
patients using the World Health Organization criteria
[17]. The physician also recorded the presence of clinical
signs and symptoms such as fever, nausea, diarrhea,
fatigue, skin rashes, oral thrush, peripheral neuropathy,
and extrapulmonary TB. A blood sample was also
obtained for measurement of hemoglobin and albumin
concentrations, CD4, CD3, and CD8 cell counts, using
FACScount and FACSCAN systems (Becton Dickinson).
Viral load was also determined using the Roche Amplicor
v1.5 assay.
Treatment failure by 1 month was defined as positive AFB
cultures 1 month after initiation of treatment. Early recur-
rence was defined as having a positive culture after 1
month after having tested culture negative by 1 month
after treatment initiation. Late recurrence was defined as
any positive culture after 8 months from treatment initia-
tion. If any of the participants missed a follow-up visit, aBMC Public Health 2009, 9:409 http://www.biomedcentral.com/1471-2458/9/409
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research assistant visited his/her home to determine sur-
vival status. The median follow-up time for HIV-unin-
fected patients was 52 months (IQR: 47-57 months) and
for HIV-infected patients was 30 months (IQR: 15-41
months).
Data Management and Statistical Analysis
All information was double entered into Fox Pro data-
bases, compared and corrected. Cox proportional hazards
models were used to assess the relationship between vari-
ous predictors and mortality. Mortality was assessed in
three groups - overall in both HIV-infected and uninfected
patients through the complete duration of follow-up; in
HIV-infected patients alone; and in HIV-infected patients
only in the first 8 months of follow-up. Variable with p-
values less than 0.2 in univariate Cox regression analyses
were included in the multivariate model; only the varia-
bles that had p-values less than 0.05 in this multivariate
model were retained in the final model. All analyses were
performed using SAS software version 9.2 (SAS Institute
Inc., Cary).
Table 1: Characteristics of the Study Population
Mortality
Yes (n = 155)N o  ( n = 732)
Characteristics Mean (SD) or % (Number) Mean (SD) or % (Number)
Social and demographic variables
Age, yrs 35.97 (8.49) 31.35 (8.84)
Females 40.00% (62) 32.10% (235)
Karnofsky Score 71.74 (9.54) 75.17 (8.41)
Shillings* spent on food/person/day (quartiles)
≤ 250 28.37% (40) 23.14% (149)
251-499 26.24% (37) 26.40% (170)
500-750 26.24% (37) 27.17% (175)
>750 19.15% (27) 23.29% (150)
TB related
AFB Smear Result positive at baseline 96.75% (149) 94.12% (688)
AFB Culture positive at baseline 66.67% (44) 68.82% (287)
Laboratory Results
Baseline Hemoglobin, g/dL 9.59 (1.59) 10.59 (1.82)
HIV- or Immune function related
HIV infected 90.32% (140) 45.22% (331)
Baseline WHO HIV stage
3 85.96% (98) 93.48% (215)
4 14.04% (16) 6.52% (15)
Baseline CD4 cell count/μL 238.15 (302.25) 564.04 (288.86)
Baseline CD3 cell count/μL 1086.23 (605.21) 1232.42 (501.09)
Baseline CD8 cell count/μL 785.61 (454.56) 601.85 (383.09)
CD4/CD8 Ratio 0.39 (0.71) 1.30 (0.90)
Log(10) viral load 5.11 (0.66) 4.38 (0.99)
Q1 6.45% (10) 11.61% (85)
Q2 14.19% (22) 9.97% (73)
Q3 18.06% (28) 9.15% (67)
Q4 34.84% (54) 5.60% (41)
Clinical signs and symptoms
Diarrhea 9.45% (12) 10.12% (58)
Fatigue 71.65% (91) 66.32% (380)
Fever 55.12% (70) 64.22% (368)
Nausea/Vomiting 5.51% (7) 8.90% (51)
Skin Rash 20.47% (26) 8.90% (51)
Oral thrush 12.60% (16) 1.40% (8)
Weight loss 81.89% (104) 80.63% (462)
Extrapulmonary TB 1.57% (2) 2.44% (14)
Anthropometry
BMI at enrolment, kg/m2 19.31 (3.04) 19.10 (2.64)
MUAC at enrolment, cm 23.25 (2.85) 23.25 (2.61)
* 1000 Tanzanian Shillings ≈ 1 US Dollar at the time of the trialBMC Public Health 2009, 9:409 http://www.biomedcentral.com/1471-2458/9/409
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Results
The characteristics of the 887 patients included in this
analysis are presented in Table 1. The mean age of patients
who died was 36 years (± 8.5) compared to 31 years (±
8.8) for patients who were alive at the end of follow-up.
40% of the patients who died were female; 32% of the
patients who were alive at the end of follow-up were
female. More than 20% of those who died had Karnofsky
scores less than 70% compared to only 9% of those who
stayed alive. The mean hemoglobin at baseline was 9.6 (±
1.6) g/dL in those who died and 10.6 (± 1.8) g/dL in those
who stayed alive. About 90% of those who died were HIV-
infected; only 45% of those who stayed alive were HIV-
infected. More than 62% of patients who died had CD4
cell counts lower than 200 cell/mm3, compared to only
11% of those who stayed alive. A greater proportion of the
patients who died had chronic diarrhea, dysentery, hospi-
tal admissions, herpes zoster, oral ulcers, peripheral neu-
ropathy, skin rash, and oral thrush compared to the
patients who survived (Table 1).
The univariate predictors (p < 0.20) of mortality in the
cohort through the complete duration of follow-up are
presented in Table 2. In the multivariate model (Table 3),
each year increase in age was associated with a 4% higher
risk of mortality (95% CI: 1.03, 1.06). Higher Karnofsky
score and baseline hemoglobin concentrations were pro-
tective against mortality in this cohort. HIV infection was
associated with a greater than 5 times increase in the risk
of mortality over the follow-up period (95% CI; 2.55,
10.55). Patients with CD4 cell counts greater than 500
cells/mm3 had 80% lower risk of dying compared to
patients with CD4 cell counts lower than 200 cells/mm3
(HR: 0.17; 95% CI: 0.09, 0.33). Similarly, patients in the
highest quartile of viral load had 4 times the risk of dying
compared to those in the lowest quartile (HR: 4.05; 95%
CI: 2.01, 8.16). Patients with oral thrush at baseline also
had a 2.5 times the risk of dying compared to the patients
who did not (95% CI: 1.40, 4.28).
Among HIV-infected patients, greater age, lower Karnof-
sky score, lesser money spent on food every day, lower
baseline hemoglobin, stage 4 HIV disease, lower CD4 and
CD3 cell counts, higher viral load, and having chronic
diarrhea, oral ulcer, peripheral neuropathy, skin rash, and
oral thrush were all associated with increased risk of mor-
tality in univariate analyses (data not shown). In the mul-
tivariate model (Table 4), greater age, lower Karnofsky
score, baseline CD3 cell count, and CD4/CD8 ratio,
higher viral load at baseline, and having oral thrush at
baseline were independent significant predictors of
increased mortality. Recruitment at Temeke center was
associated with a significantly higher risk of mortality
compared to the other four centers. The presence of nau-
sea/vomiting at baseline was associated with reduced
mortality in this HIV-infected cohort.
When analyses was restricted to the first 8 months of fol-
low-up (the treatment phase) in the HIV-infected patients
in this cohort, the univariate predictors of mortality
remained largely similar (data not shown). In the multi-
variate model (Table 5), however, viral load and nausea/
vomiting did not remain as predictors. Height group (in
quartiles) was found to be a significant independent pre-
dictor of mortality; the patients in quartile 3 had a 2.6
times higher risk of mortality compared to those in quar-
tile 1 (95% CI: 1.01, 6.70).
Discussion
Mortality among TB patients infected with HIV during
and following completion of anti-TB treatment in the
absence of ART remains high as confirmed by this study.
Older age, HIV infection, lower Karnofsky scores, hemo-
globin levels, and CD4 cell counts, higher viral load, and
oral thrush were independent predictors of mortality in
this analysis. Among HIV-infected patients, older age,
lower Karnofsky score, CD3 cell counts, and CD4/CD8
ratio, higher viral load, recruitment at Temeke, and oral
thrush were independent predictors of mortality. Presence
of nausea/vomiting was protective against death in these
patients.
The overall mortality of 17.5% in this study was mainly
contributed by a high mortality rate among HIV-infected
patients (29.7%) as opposed to comparatively low mor-
tality (3.6%) among HIV-uninfected patients; over 90%
(140/155) of the deaths were among the HIV-infected
patients. This high mortality occurred despite the use of a
highly effective Rifampicin containing DOTS regimen for
2 months as part of initial intensive therapy. Similar high
mortality rates during and after TB treatment among HIV-
infected patients with smear-positive pulmonary TB have
been reported in a number of studies in sub Saharan
Africa [18]. Harries et al estimated that in sub Saharan
Africa, up to 30% of HIV-infected TB patients die within
12 months of starting anti TB treatment [7]. The mortality
rate among HIV-infected patients with TB, particularly
among those with no access to anti-retroviral treatment
(ART), is similar in other parts of the world as well. For
example, in a study in Cambodia, 27% of HIV-infected
patients with TB died during follow-up [19]. In a large
trial in US and Canada, 29.6% of HIV-infected TB patients
who did not receive any ART died during follow-up (28
months) [20].
Excess deaths in HIV-infected TB patients in this study
were probably caused by conditions other than TB, most
likely by HIV-related causes [7]. While deaths during treat-
ment may be considered to be due to TB, deaths occurringBMC Public Health 2009, 9:409 http://www.biomedcentral.com/1471-2458/9/409
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Table 2: Univariate Predictors of Mortality (p < 0.20)
Univariate Analyses
Characteristics Hazard Ratio (HR) p-value1
Social and demographic variables
Age, years 1.05 (1.03, 1.06) <0.01
Sex
Females 1.45 (1.05, 2.00) 0.02
Karnofsky Score 0.96 (0.94, 0.97) <0.01
Karnofsky Score <70% 2.43 (1.64, 3.60) <0.01
Shillings spent on food/person/day 1 (0.999, 1) 0.09
TB related
AFB Smear at baseline - Number of colonies 0.01
Negative 1
1-9/100 fields 2.88 (0.94, 8.82)
10-99/100 fields 2.15 (0.86, 5.37)
1-10/field 2.22 (0.88, 5.62)
>10/field 1.20 (0.47, 3.01)
Early Relapse2 1.60 (0.80, 3.19) 0.18
Treatment failure 1 month post-treatment initiation 0.47 (0.25, 0.88) 0.02
Has ever had TB 0.70 (0.51, 0.97) 0.03
Received TB treatment in the past 5 years 1.96 (0.96, 4.00) 0.06
Laboratory Results
Baseline Hemoglobin, g/dL 0.73 (0.67, 0.80) <0.01
Baseline Albumin, g/L 0.83 (0.71, 0.97) 0.02
HIV- or Immune function related
HIV infected 12.40 (7.24, 21.23) <0.01
Baseline HIV stage
3 1
4 1.94 (1.14, 3.29) 0.01
Patient progressed from stage 3 to 4 1.91 (1.28, 2.84) <0.01
Baseline CD4, per 100 cells/μL 0.57 (0.52, 0.63) <0.01
CD4 cell count, cells/μL <0.01
0-199 1
200-499 0.14 (0.09, 0.22)
>=500 0.04 (0.02, 0.07)
Baseline CD3, per 100 cells/μL 0.94 (0.90, 0.98) <0.01
Baseline CD8, per 100 cells/μL 1.10 (1.06, 1.14) <0.01
CD4/CD8 Ratio 0.09 (0.05, 0.15) <0.01
RNA Viral load, per 10,000 copies/ml 1.02 (1.02, 1.03) <0.01
Log(10) viral load 2.70 (2.05, 3.54) <0.01
Log(10) viral load, quartiles <0.01
Q1 1
Q2 2.54 (1.20, 5.37)
Q3 3.67 (1.78, 7.56)
Q4 8.63 (4.38, 17.00)
Clinical signs and symptoms
Depression >2 weeks, ever 1.45 (0.84, 2.52) 0.19
Chronic Diarrhea 7.88 (3.22, 19.29) <0.01
Dysentery 2.22 (1.08, 4.53) 0.03
Fever 0.66 (0.47, 0.94) 0.02
Hospital admission 2.01 (0.94, 4.30) 0.07
Herpes Zoster, first episode 2.13 (0.79, 5.77) 0.14
Kaposi's Sarcoma 6.48 (1.60, 26.24) 0.01
Oral Ulcer 2.64 (1.16, 5.99) 0.02
Nausea/Vomiting 0.59 (0.28, 1.27) 0.18
Oropharyngeal candidiasis 5.16 (1.90, 13.99) <0.01
Oral candidiasis 6.90 (4.07, 11.72) <0.01
Peripheral Neuropathy 1.84 (1.04, 3.27) 0.04
Skin Rash 2.30 (1.49, 3.54) <0.01
Oral thrush 7.35 (4.33, 12.48) <0.01
Anthropometry
Height, cm 0.97 (0.96, 0.99) <0.01
Triceps Skinfold, average of 3 measurements 1.03 (1.00, 1.07) 0.04
1 p-values obtained from Cox Regression Analyses
2 Relapse between 1-8 months post-treatment initiation if culture negative at 1 month (Early Relapse)BMC Public Health 2009, 9:409 http://www.biomedcentral.com/1471-2458/9/409
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after successful completion of TB treatment can be consid-
ered to be due to factors other than TB such as HIV-related
causes. In this study only 25.7% (36/140) of deaths in the
HIV-infected patients occurred during the 8 months of
anti-TB therapy while the rest 74.3% (104/140) occurred
after successful completion of their therapy. Although the
cause of mortality is difficult to confirm in the absence of
autopsy, as was the case in this study, the presence of
advanced HIV disease in patients receiving potent anti-TB
therapy, suggests that deaths in most cases occurred from
diseases other than TB. Therefore, it is extremely impor-
tant to ensure delivery of HAART to HIV-infected patients
with TB. Several studies have shown a dramatic decline in
mortality rates with introduction of HAART in this group
of patients. For example, age- and sex-standardized mor-
tality rates decreased from 22.9% to 11.8% between 1993-
95 and 1999-2001 in the Netherlands, probably because
of widespread availability of HAART by 1999 [21]. Other
studies have also shown that HAART may reduce the mor-
tality in HIV-infected TB patients by as much as 60% [22].
Only 10.5% of the patients who received HAART died
during follow-up compared to 29.6% of those who did
not receive any ART in a study from North America [20].
Older age is a well-established risk factor for mortality
among TB patients [23-27]. For example, patients 55 years
or older had a 2.4 times increased risk of dying in multi-
variate analyses, compared to patients between the ages of
15-24 in a study in Guinea-Bissau [12]. Similarly, in a
study in Singapore, older age (≥ 65 years) was associated
with 8 times the risk of mortality compared to younger
patients (<45 years) [28].
HIV sero-status has been reported to be the most impor-
tant factor associated with mortality both during and after
treatment among patients with smear positive pulmonary
TB [20,23,25,29-31]. In a study from Guinea-Bissau, HIV-
1 infection was associated with approximately 5 times
greater risk of mortality compared to uninfected TB
patients [12]; this effect size is similar to our results. Low
CD4 cell counts have also been shown to increase the risk
of mortality among TB patients [32]; in a study in Uganda,
low CD4 cell count at baseline among HIV-infected TB
patients initiating ART was the only significant independ-
ent predictor of mortality [33].
The presence of TB in HIV infected patients is likely to
accelerate the progression of HIV disease. TB infection and
disease stimulates the host immune system including rep-
lication of T-lymphocytes, which subsequently enhances
viral replication leading to high viral load. Low CD4 cell
counts coupled with a high viral load are associated with
faster HIV disease progression making patients suscepti-
ble to opportunistic illnesses, which may have been the
cause of death despite successful TB treatment. Similarly,
Karnofsky score could represent how sick the patients
were at baseline; lower Karnofsky score implies advanced
disease and thus may explain its association with higher
risk of death. Presence of diseases such as oral thrush
[12,32] also indicates immunocompromise in the patient
and suggests that these patients had more advanced dis-
ease at baseline, leading to greater mortality.
Recruitment at the Temeke center could possibly be
explained by it being a bigger hospital and hence attract-
ing sicker patients from adjoining areas. The presence of
nausea/vomiting being protective against mortality in
Table 3: Multivariate Predictors of Mortality (p < 0.05)
Multivariate Analyses
Characteristics Hazard Ratio (HR) p-value1
Age, years 1.04 (1.03, 1.06) <0.01
Karnofsky Score 0.98 (0.96, 1.00) 0.02
Baseline Hemoglobin, g/dL 0.87 (0.79, 0.96) <0.01
HIV infected 5.18 (2.55, 10.55) <0.01
CD4 groups, cells/μL <0.01
0-199 1
200-499 0.27 (0.17, 0.41)
>=500 0.17 (0.09, 0.33)
Log(10) viral load, quartiles <0.01
Q1 1
Q2 1.78 (0.84, 3.79)
Q3 2.64 (1.27, 5.48)
Q4 4.05 (2.01, 8.16)
Oral thrush 2.45 (1.40, 4.28) <0.01
1 p-values obtained from Cox Regression Analyses
Table 4: Multivariate Predictors of Mortality among HIV-
infected patients (p < 0.05)
Multivariate Analyses
Characteristics Hazard Ratio (HR) p-value1
Age, years 1.03 (1.01, 1.05) 0.01
Center 0.01
Mwananyamala 0.50 (0.31, 0.82)
Temeke 1
Tandale 0.57 (0.36, 0.92)
Mbgala 0.94 (0.51, 1.74)
Amana 0.50 (0.28, 0.89)
Karnofsky Score 0.98 (0.96, 0.99) 0.01
Baseline CD3, per 100 cells/μL 0.95 (0.92, 0.99) 0.01
CD4/CD8 Ratio, per 0.1 change 0.61 (0.54, 0.70) <0.01
Log(10) viral load, quartiles <0.01
Q1 1
Q2 1.52 (0.71, 3.27)
Q3 2.60 (1.23, 5.49)
Q4 3.17 (1.57, 6.41)
Nausea/Vomiting 0.28 (0.10, 0.84) 0.02
Oral thrush 3.17 (1.76, 5.72) <0.01
1 p-values obtained from Cox Regression AnalysesBMC Public Health 2009, 9:409 http://www.biomedcentral.com/1471-2458/9/409
Page 7 of 8
(page number not for citation purposes)
HIV-infected TB patients is novel and we did not find any
studies presenting a similar association.
We also found that lower baseline hemoglobin was asso-
ciated with mortality in this group of patients. This is in
accordance with other studies which have found a similar
association; for example, a study in Samara, Russia, found
that anemia (defined as hemoglobin <12 g/dL in males
and <11 g/dL in females) was associated with 5 times
greater odds of dying among TB patients [34]. In another
study conducted in Malawi and Zambia, the investigators
found that hemoglobin levels >10 g/dl in HIV-infected
patients with TB were associated with almost 80% reduc-
tion in risk of mortality during and after anti-TB treatment
[35]. In our earlier work, we have shown that anemia is an
independent risk factor of mortality in HIV-infected
patients in Tanzania [36]; this has also been shown in
studies from Europe [37].
Measures to prevent deaths in TB patients in countries
with high HIV prevalence should include the use of; 1)
antiretroviral therapy (ART), which is likely to have the
greatest impact; 2) TB treatment regimens of proven effec-
tiveness; 3) preventive therapy for HIV-related diseases
other than TB; 4) improved TB and HIV control services;
and 5) improved general health services with better diag-
nosis and treatment of HIV-related diseases [8].
The wide spread use of ART is expected to be associated
with the reduction in mortality from HIV related diseases
including TB. Irrespective of the proportions of deaths
that are due to TB or to other HIV-related diseases, TB
deaths in high HIV prevalence populations represent a
joint failure of TB and HIV programs. National TB Pro-
grams face the challenge not only of ensuring the effective
diagnosis and treatment of increasing numbers of TB
patients, but also of trying to identify and implement
ways of reducing TB deaths in collaboration with HIV pro-
grammes [6,7].
Conclusion
This study has demonstrated that
1. Mortality among TB patients co-infected with HIV is
still high in the absence of ART despite adequate treat-
ment using potent anti-TB drugs.
2. Most patients died after successful completion of their
anti TB therapy indicating that TB was less likely to be the
cause of death.
3. HIV sero-status, older age, Karnofsky score, low hemo-
globin levels and CD4 cell counts, higher viral load, and
oral thrush at baseline are predictors of mortality among
TB patients.
4. Older age, Karnofsky score, low CD3 cell counts and
CD4/CD8 ratio, high viral load, oral thrush, and absence
of nausea/vomiting at baseline are predictors of mortality
among TB and HIV co-infected patients.
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